Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast
He predicted the 2020 crash a month before it happened…He predicted this year’s collapse back in January…

And now, he’s issuing a brand-new warning – along with a unique solution.
Details here.
Jeroen B. Van Beek net worth and biography

Jeroen Van Beek Biography and Net Worth

Insider of AlloVir
eroen van Beek, Ph.D., has served as our Chief Commercial Officer since January 2019. Before joining AlloVir, Dr. van Beek was the Chief Commercial Officer and Senior Vice-President at Tricida in charge of commercial strategy, planning and operations from January 2018 to September 2018. From 2007 to 2017, Dr. van Beek worked at Alexion Pharmaceuticals, most recently as the Vice-President of Global Commercial Operations and Development in charge of the global Soliris® franchise. He was also responsible for the lifecycle management of Soliris® and the commercial development and positioning of Alexion’s portfolio of next-generation complement inhibitors.

During his tenure at Alexion, Dr. van Beek led the launches for Soliris® in two rare diseases: the blood disorder Paroxysmal Nocturnal Hemoglobinuria and the kidney disease atypical Hemolytic Uremic Syndrome.

From 1999 to 2007, Dr. van Beek held positions of increasing commercial responsibility at Pfizer including Marketing Director, Oncology responsible for launching Sutent® for renal cell carcinoma and gastrointestinalstromal tumor.

Dr. van Beek received his B.S. in Chemistry from the University of Virginia, his Ph.D. in Chemistry from Cornell University, and his M.B.A.from the Darden Business School at the University of Virginia.

What is Jeroen B. Van Beek's net worth?

The estimated net worth of Jeroen B. Van Beek is at least $2.86 million as of August 16th, 2022. Dr. Van Beek owns 386,363 shares of AlloVir stock worth more than $2,855,223 as of September 26th. This net worth estimate does not reflect any other investments that Dr. Van Beek may own. Learn More about Jeroen B. Van Beek's net worth.

How do I contact Jeroen B. Van Beek?

The corporate mailing address for Dr. Van Beek and other AlloVir executives is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. AlloVir can also be reached via phone at 617-433-2605 and via email at [email protected] Learn More on Jeroen B. Van Beek's contact information.

Has Jeroen B. Van Beek been buying or selling shares of AlloVir?

Jeroen B. Van Beek has not been actively trading shares of AlloVir during the past quarter. Learn More on Jeroen B. Van Beek's trading history.

Who are AlloVir's active insiders?

AlloVir's insider roster includes Ercem Atillasoy (Insider), Jeffrey Bornstein (Director), Brett Hagen (CAO), David Hallal (Director), Morana Jovan-Embiricos (Director), Ann Leen (Insider), Agustin Melian (Insider), Jeroen Van Beek (Insider), Juan Vera (Director), and John Wilson (Director). Learn More on AlloVir's active insiders.

Are insiders buying or selling shares of AlloVir?

In the last year, AlloVir insiders bought shares 2 times. They purchased a total of 10,000 shares worth more than $67,550.00. In the last year, insiders at the sold shares 27 times. They sold a total of 239,428 shares worth more than $2,983,171.15. The most recent insider tranaction occured on August, 18th when CEO Diana Brainard sold 4,564 shares worth more than $35,416.64. Insiders at AlloVir own 54.2 % of the company. Learn More about insider trades at AlloVir.

Information on this page was last updated on 8/18/2022.

Jeroen B. Van Beek Insider Trading History at AlloVir

See Full Table

Jeroen B. Van Beek Buying and Selling Activity at AlloVir

This chart shows Beek Jeroen B. Van's buying and selling at AlloVir by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AlloVir Company Overview

AlloVir logo
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $7.39
Low: $7.05
High: $7.61

50 Day Range

MA: $7.06
Low: $4.59
High: $8.79

2 Week Range

Now: $7.39
Low: $3.17
High: $26.41

Volume

186,100 shs

Average Volume

900,127 shs

Market Capitalization

$687.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast
He predicted the 2020 crash a month before it happened…He predicted this year’s collapse back in January…

And now, he’s issuing a brand-new warning – along with a unique solution.
Details here.